Current research in MSI-H focuses on understanding the molecular mechanisms underlying DNA mismatch repair deficiency and identifying new therapeutic targets. Scientists are also exploring the use of MSI-H as a biomarker for predicting treatment response and disease prognosis. Additionally, ongoing clinical trials are investigating the efficacy of combining immunotherapy with other treatments to enhance anti-tumor responses in MSI-H cancers.
